Treatment of XXXX with autologous blood stem cell transplantation. Preliminary results of an Italian multicentric pilot study.

@entity1 @entity137 @entity1261 @entity55 @entity1582 @entity2834 @entity2280
Starting from May, 1991, 35 untreated @entity1582 @entity1 entered a multicentric pilot study to evaluate the feasibility of a program of PBSC transplantation for previously untreated @entity1582 @entity1 . The schedule was as follows: 2 cycles of VAD followed by CY, 7 g/mq+ @entity1261 (Granulokine, Roche) for 14 days, to increase and collect PBSC. The subsequent conditioning regimen was Melphalan+Busulfan followed by @entity1261 . As maintenance R alpha-2 IFN was given, until relapse. The median follow-up is 14 months (4-22). On April 1993, 34 @entity1 received at least 2 cycles of VAD, 27 were submitted to PBSC collection, 22 received conditioning regimen plus PBSC and 16 of them are in the maintenance treatment with IFN. Considering 28 @entity1 for an intention to treat evaluation (35-7 in treatment), responding @entity1 are 71% with 46% who achieved CR. White cells and platelets raised to > 1000/mmc and > 50,000/mmc after a median period of 10 and 13 days, from CY, and 11 and 14 days from transplant, respectively. Two @entity1 relapsed, 2 others died while in PR because of @entity2834 epatitis and @entity55 . The median number of @entity2280 + cells and CFU-GM was 24.75 x 10(6)/kg b.w. and 28.1 x 10(4)/kg b.w. respectively. In conclusion this treatment seems to be feasible and with low @entity137 , but a longer follow-up is needed to evaluate the progression free survival of the high proportion of responding @entity1 that we observed.
